Business Wire

MYbank Unveils Five-Year Plan to Reach More SMEs Across China via Supply Chain Finance and Rural Lending

Share

MYbank, a leading online private commercial bank under Ant Group, today announced a five-year plan to reach more small and micro enterprises (SMEs) across China via supply chain finance and rural lending.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630005465/en/

The number of SMEs served by MYbank increased more than tenfold in five years (Graphic: Business Wire)

The number of SMEs served by MYbank increased more than tenfold in five years (Graphic: Business Wire)

The five-year plan details MYbank’s aspirations to work with partners across multiple sectors to better serve SMEs across China. Key measures and initiatives MYbank will implement as part of the plan include:

  • Leveraging supply chain finance to support 10 million SMEs who traditionally have been unserved or underserved in the market.
  • Working with 2,000 county and village managers to provide rural lending to SMEs in need.
  • Collaborating with financial institution partners to distribute interest-free vouchers for business loans totaling RMB 300 billion.
  • Serving 40 million female business owners and providing them with more economic opportunities.

“Through this five-year plan, we look forward to working with more financial institution partners to realize our shared vision to make financial services more accessible for SMEs,” said Xiaolong Jin, President of MYbank. “In the past, SMEs had to go through a one-way application approval process when they came to us for lending services. By working with our partners and embedding our services seamlessly into use cases such as supply chain finance and rural lending, we hope to bring our services to SMEs across a wide spectrum of industries.”

Established on June 25, 2015, MYbank is one of the leading private online commercial banks in China focused on serving SMEs and farmers. It was the first bank in China to establish its core banking system entirely on the cloud without any physical branches. Leveraging Ant Group’s AI, computing and risk management technologies, MYbank also pioneered the “310 model” for SME financing, which offers collateral-free business loans that take less than three minutes to apply for on a mobile phone, less than one second to approve, and requires zero human intervention. SMEs in China supported by the “310 model” have shown resilience during the COVID-19 pandemic, with 98% of them repaying their loans on time.

According to data from the People’s Bank of China (PBOC), SMEs account for over 90% of business entities in China and contribute to 80% of urban employment and 60% of Chinese GDP. As of June 2020, MYbank and its partners have served 29 million SMEs in China, including street vendors. Their average loan size is RMB 36,000 (approximately USD$5,000) and 80% of them had previously never received business loans from a bank.

Leveraging Ant Group’s blockchain technology, Log56.com, a Chinese logistics platform with 70,000 registered corporate users, has helped 200,000 truck drivers and micro logistics business owners successfully apply for loans from MYbank and its financial institutional partners. Ant’s blockchain technology helped to ensure key logistics information, such as order and execution numbers, are tamper-proof. This also reduced costs related to risk management and helped MYbank’s AI to calculate an accurate line of credit for SME operators on the platform.

Jinmailang Food, a Chinese food manufacturing company, has over 5,000 distributors across its supply chain. Many of these distributors had to suspend their operations during the COVID-19 pandemic. To help these distributors cope with the economic impact of the pandemic, Jinmailang introduced MYbank and its “310 model” to help them prepare for recovery in the post-COVID-19 era. Using key operational data provided by Jinmailang, such as order fulfillment and logistics records, MYbank was able to extend lines of credit to SME distributors so that they can use the short-term funding to restock from the food producer. This also served to ensure the funding will be used solely for economic recovery purposes.

MYbank has implemented a series of measures to help small and micro business owners overcome the economic impact of the COVID-19 pandemic, including waiving or lowering interest rates. In March, MYbank partnered with 100 banks to launch the “Contactless Loans” initiative to support SMEs as they resume operations and overcome the impact of COVID-19. According to the China Banking Association, the initiative had served over 10 million SMEs and extended loans totaling RMB 400 billion as of the end of April 2020.

Contact information

Bell Wang
E: yixing.wl@antfin.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xerox Launches ConnectKey-Enabled AltaLink Digital Workplace Assistant15.7.2020 18:47:00 CESTPress release

Xerox announced its new https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.office.xerox.com%2Fen-us%2Fmultifunction-printers%2Faltalink-c8100-series&esheet=52250531&newsitemid=20200715005746&lan=en-US&anchor=Xerox+AltaLink%26%23174%3B+C8100&index=1&md5=59e47e2191588f21b4da900931086697 Xerox AltaLink® C8100 and Xerox AltaLink B8100 Series multi-function printers (MFPs), that can better support today’s flexible work environment and help companies speed their digital transformation with access to the ConnectKey® ecosystem of apps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200715005746/en/ The tablet-like user interface allows for easy, familiar interaction or the user can choose to print from their mobile devices. (Photo: Business Wire) In addition to its printing capabilities, the AltaLink 8100 series helps speed workplace digitization with ultra-fast scanning of up to 270 images per minute and Optical

Bureau Veritas Launches a New Solution to Improve Supply Chain Resilience15.7.2020 17:45:00 CESTPress release

Bureau Veritas, a world leader in testing, inspection and certification (TIC) services, is launching Supply-R, a solution designed to meet companies’ new challenges relating to supplier network reliability and ensuring business continuity in all circumstances. Organizations learned multiple lessons during the first half of 2020 on the resilience of global supply chains and their ability to face disruptions. There is an urgent need from many companies to reassess their supply chain risk, based on factual data from the field, to make sure that all elements are properly addressed, assessed and visible. Bruno Ferreyra, Executive Vice-President at Bureau Veritas, commented: "Economic globalization means supply chains include more suppliers and intermediaries than before, and they are scattered around the globe. This makes each step, process and stakeholder in the manufacturing chain harder to track. Our goal is to support businesses, mapping out their supply chains to give them complete con

VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors15.7.2020 17:40:00 CESTPress release

Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible) a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study designed to assess TOTUM-63 for the reduction of Type 2 Diabetes metabolic risk factors. Murielle CAZAUBIEL, member of the Management Board and Director of Development and Medical Affairs at VALBIOTIS, comments: "The first visit of this first subject, a few days after obtaining both ANSM1 approval and the favorable decision from the CPP2, marks the concrete launch of the REVERSE-IT study, the results of which are expected in mid-2022. We are right on schedule and are delighted to be able to enter the operational phase of this major study so quickly. We also welcome the enthusiasm and commitment of all the partner investigation centers." Dr Hans-Juergen WOERLE, Chief Scientific and Medical Off

Octapharma Reports Positive Data from octagam ® Usage in Critically Ill COVID-19 Patients15.7.2020 17:04:00 CESTPress release

Topline results from a retrospective study in 93 critically ill COVID-19 patients have become available. The data shows that IVIG treatment reduces inflammation, which is associated with poor clinical outcomes and death, and points to an increase in survival, in critically ill COVID-19 patients, when compared to a control group. The study was conducted at the Istanbul University Hospital, Turkey, under the lead of Prof. Dr. Figen Esen. In critically ill COVID-19 patients, the cause of death often implicates an abnormal pulmonary immune response. This abnormal immune response is characterized by high levels of inflammatory markers, which are associated with poor clinical outcomes.1, 2 Acute respiratory distress syndrome (ARDS) and multiorgan failure are major causes of mortality in COVID-19 patients.3 High levels of pro-inflammatory cytokines and chemokines are part of a severe inflammatory response known as a “cytokine storm” which may cause multiple organ dysfunction and ARDS in criti

European Commission approves third nintedanib indication in pulmonary fibrosis 115.7.2020 15:34:00 CESTPress release

Boehringer Ingelheim today announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1 The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020.3 The U.S. Food and Drug Administration (FDA), Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) recently approved nintedanib as the first treatment for the same patient population.4,5,6 Interstitial lung diseases encompass a large group of more than 200 disorders that may involve the threat of pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function.7 People living with fibrosing ILD can develop a progressive phenotype, leading to lung function decline, deterioration in quality of life and early mortality simila

With U.S. Cotton Trust Protocol, Brands and Retailers Can Now Source U.S. Cotton with More Confidence15.7.2020 15:05:00 CESTPress release

Startingtoday, brands and retailers can join the U.S. Cotton Trust Protocol, a new system for responsibly grown cotton that will provide annual data for six areas of sustainability in line with the U.N. Sustainability Goals. This year-over-year data, available for the first time, will allow brands and retailers to better measure progress towards meeting sustainability commitments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200715005278/en/ (Graphic: Business Wire) “One of our goals in developing the Trust Protocol is to give brands and retailers greater confidence when including U.S. cotton in their sourcing mix,” said Ken Burton, Executive Director of the U.S. Cotton Trust Protocol. “Participating brands and retailers will now be able to demonstrate measurable progress in reducing their environmental footprint and in achieving sustainability targets.” The Trust Protocol underpins and verifies sustainability progress thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom